Blueprint
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 20 March
2017
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc
Annual Report 2016 on Form 20-F
In accordance with Section 203.01 of the New York Stock Exchange
Listed Company Manual, GlaxoSmithKline plc ("GSK") announces that
on 17 March 2017 it filed with the Securities and Exchange
Commission an Annual Report on Form 20-F that included audited
financial statements for the year ended 31 December 2016. GSK's
2016 Annual Report on Form 20-F is available online at GSK's
website at www.gsk.com/corporatereporting
and also online at
www.sec.gov.
Ordinary
Shareholders may also elect to receive notification by email of the
publication of financial reports by registering on www.shareview.co.uk.
A hard
copy version of the GSK 2016 Annual Report, together with the
Annual Summary and Notice of Annual General Meeting will be
available on or about 30 March 2017.
Shareholders
have the ability to receive, upon request, a hard copy version of
GSK's complete audited financial statements for the year ended 31
December 2016, free of charge, by either:
(i)
writing to Equiniti
Limited, our registrars in the UK, at the following address:
Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex
BN99 6DA, or by telephone on 0371 384 2991 (inside the UK) or +44
(0)121 415 7067 (outside the UK);
(ii)
writing to The Bank
of New York Mellon, our ADR depositary in the US, at the following
address: BNY Mellon, Shareholder Services, Receipts, PO Box 30170,
College Station, Texas, TX 77842-3170, or by telephone on +1 877
353 1154 (US toll free) or +1 201 680 6825 (outside the US);
or
(iii)
contacting the GSK
Response Center in the USA at +1 888 825 5249 (US toll
free).
Victoria Whyte
Company Secretary
17 March 2017
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors' in the company's Annual Report on Form 20-F for
2016.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: March
20, 2017
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|